Is Osimertinib effective against bone metastasis?

Bone metastases are common in non-small cell lung cancer patients with EGFR mutations (EGFR+). Skeletal-related events (SREs) are common in these patients; however, no data on skeletal-related events (SREs) have been reported in patients treated with Osimertinib. Because of these findings and the poor long-term overall survival after bone metastasis, the use of bone-targeted agents in these patients is advocated and the addition of bone-specific endpoints to clinical trials is recommended.

A total of250 patients received osimertinib. Among these patients, 51% developed bone metastases when starting osimertinib. In addition, 16% of patients with bone metastases received bone-targeting drugs. The median follow-up time from the start of osimertinib was 23.4 months. During treatment, 10% developed new bone metastases or bone progression. Among patients with bone metastases, 39% had more than or equal to one SRE, 28% had their first SRE before osimertinib treatment, 1% after treatment, and 11% during treatment. The median OS after bone metastasis was 30.8 months. The median OS after the first SRE was 31.1 months.

OsimertinibThe original drug has been launched in China and has entered the scope of medical insurance. Its name is Osimertinib Mesylate Tablets. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. SpecificationThe price of 80mg*30 tablets per box is around RMB 5,000, which is relatively expensive. The original drug of Osimertinib has also been launched overseas, and there are also generics of Osimertinib produced in other countries. For example, the price of 80mg*30 tablets per box produced by Bangladesh Yaopin International is around RMB 850 (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of the generic Osimertinib and the original drug are basically the same.